Trials / Completed
CompletedNCT00425347
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Facet Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HuLuc63 | Not applicable for HuLuc63. |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-08-01
- Completion
- 2009-07-01
- First posted
- 2007-01-22
- Last updated
- 2009-09-23
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00425347. Inclusion in this directory is not an endorsement.